![Manel Cascalló](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Manel Cascalló
Corporate Officer/Principal chez THERIVA BIOLOGICS, INC.
Postes actifs de Manel Cascalló
Sociétés | Poste | Début | Fin |
---|---|---|---|
THERIVA BIOLOGICS, INC. | Corporate Officer/Principal | 23/03/2022 | - |
Historique de carrière de Manel Cascalló
Anciens postes connus de Manel Cascalló
Sociétés | Poste | Début | Fin |
---|---|---|---|
VCN Biosciences SL
![]() VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Directeur Général | - | - |
Président | - | - |
Formation de Manel Cascalló
University of Barcelona | Doctorate Degree |
Statistiques
Internationale
Espagne | 3 |
Etats-Unis | 2 |
Opérationnelle
Chief Executive Officer | 1 |
Chairman | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Consumer Services | 2 |
Health Technology | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
THERIVA BIOLOGICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
VCN Biosciences SL
![]() VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Commercial Services |
- Bourse
- Insiders
- Manel Cascalló
- Expérience